RARRES2 and acute myeloid leukemia: Kaplan-Meier analysis results showed that patients with low chemerin expression had poorer overall survival (OS) than those with high chemerin expression in whole AML patients (median 5.5 vs 16.5 months, respectively, P=0.049, Figure 3).